Pain management of the cancer patient

Bibliography

• Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin 2011;61(3):157-82
   PubMed Web of Science ®Google Scholar
• Denlinger CS, Ligibel JA, Are M, et al. Survivorship: pain version 1.2014. J Natl Compr Canc Netw 2014;12(4):488-500
   Google Scholar
• Puchalski CM. Religion, medicine and spirituality: what we know, what we don’t know and what we do. Asian Pac J Cancer Prev 2010;11(Suppl 1):45-9
   Google Scholar
• Choi M, Kim HS, Chung SK, et al. Evidence-based practice for pain management for cancer patients in an acute care setting. Int J Nurs Pract 2014;20(1):60-9
   PubMed Web of Science ®Google Scholar
• Balding L. The World Health Organisation analgesic ladder: its place in modern Irish medical practice. Ir Med J 2013;106(4):122-4
   Google Scholar
• Gaertner J, Schiessl C. Cancer pain management: what’s new? Curr Pain Headache Rep 2013;17(4):328
   Google Scholar
• Marcus DA. Epidemiology of cancer pain. Curr Pain Headache Rep 2011;15(4):231-4
   PubMed Web of Science ®Google Scholar
• Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest 2005;23(2):182-90
   PubMedGoogle Scholar
• Foley KM. How well is cancer pain treated? Palliat Med 2011;25(5):398-401
   PubMedGoogle Scholar
• Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann oncol 2012;23(Suppl 7):vii139-54
   PubMed Web of Science ®Google Scholar
• Cohen E, Botti M, Hanna B, et al. Pain beliefs and pain management of oncology patients. Cancer Nurs 2008;31(2):E1-8
   Web of Science ®Google Scholar
• Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol 2014;32(16):1727-33
   PubMed Web of Science ®Google Scholar
• Fallon MT. Neuropathic pain in cancer. Br J Anaesth 2013;111(1):105-11
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fainsinger R, Kaasa S. Assessment and classification of cancer pain. Curr Opin Support Palliat Care 2009;3(1):24-30
   PubMedGoogle Scholar
• Knudsen AK, Aass N, Fainsinger R, et al. Classification of pain in cancer patients–a systematic literature review. Palliat Med 2009;23(4):295-308
   PubMed Web of Science ®Google Scholar
• Burton AW, Chai T, Smith LS. Cancer pain assessment. Curr Opin Support Palliat Care 2014;8(2):112-16
   Google Scholar
• Stewart J. The challenges of cancer pain assessment. Ulster Med J 2014;83(1):44-6
   PubMedGoogle Scholar
• Auret K, Schug SA. Pain management for the cancer patient - current practice and future developments. Best Pract Res Clin Anaesthesiol 2013;27(4):545-61
   Google Scholar
• Twycross R. Cancer pain classification. Acta Anaesthesiol Scand 1997;41(1 Pt 2):141-5
   PubMed Web of Science ®Google Scholar
• Caraceni A, Portenoy RK, Ashby MA, et al. An international survey of cancer pain characteristics and syndromes. Pain 1999;82(3):263-74
   PubMed Web of Science ®Google Scholar
• Leppert W. Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag Res 2010;2:225-32
   PubMedGoogle Scholar
• Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage 2014;48(4):619-31
   PubMed Web of Science ®Google Scholar
• Abbey J, Piller N, De Bellis A, et al. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs 2004;10(1):6-13
   PubMedGoogle Scholar
• WHO. Cancer pain relief. World Health Organisation; Geneva: 1986
   Google Scholar
• WHO. Cancer pain relief: with a guide to opioid availability. 2nd edition. World Health Organisation; Geneva: 1996
   Google Scholar
• Schug S, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5(1):27-32
   Google Scholar
• Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63(1):65-76
   PubMed Web of Science ®Google Scholar
• Cherny NI. The pharmacologic management of cancer pain. Oncology (Williston Park, NY) 2004;18(12):1499-515; discussion 516, 520-1, 522, 524
   Google Scholar
• Aapro M, Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2012;38(3):235-40
   Google Scholar
• Fielding F, Sanford TM, Davis MP. Achieving effective control in cancer pain: a review of current guidelines. Int J Palliat Nurs 2013;19(12):584-91
   Google Scholar
• McGeeney BE. Adjuvant agents in cancer pain. Clin J Pain 2008;24(Suppl 10):S14-20
   Google Scholar
• Mercadante S, Giarratano A. The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: a critical review. Crit Rev Oncol Hematol 2013;87(2):140-5
   PubMedGoogle Scholar
• Nabal M, Librada S, Redondo MJ, et al. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med 2012;26(4):305-12
   Google Scholar
• Blieden M, Paramore LC, Shah D, Ben-Joseph R. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol 2014;7(3):341-8
   PubMed Web of Science ®Google Scholar
• Wang XM, Hamza M, Wu TX, Dionne RA. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: correlation to clinical pain. Pain 2009;142(3):275-83
   Google Scholar
• Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001;27(1):51-61
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011;9:CD008659
   Google Scholar
• Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010;110(4):1170-9
   PubMed Web of Science ®Google Scholar
• Lafrance JP, Miller DR. Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. Pharmacoepidemiol Drug Saf 2009;18(10):923-31
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ, Paling J. What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. Arthritis Res Ther 2008;10(1):R20
   PubMedGoogle Scholar
• McCarberg BH. NSAIDs in the older patient: balancing benefits and harms. Pain Med 2013;14(Suppl 1):S43-4
   Google Scholar
• Freynhagen R, Zenz M, Strumpf M. [WHO step II - clinical reality or a didactic instrument?]. Schmerz 1994;8:210-15
   Google Scholar
• Maltoni M, Scarpi E, Modonesi C, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005;13(11):888-94
   Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2):e58-68
   PubMed Web of Science ®Google Scholar
• Liu HC, Liu TJ, Yang YY, Hou YN. Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. Acta Pharmacol Sin 2001;22(1):91-6
   Google Scholar
• Lai J, Ma SW, Porreca F, Raffa RB. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 1996;316(2-3):369-72
   PubMed Web of Science ®Google Scholar
• Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 2009;61(6):978-92
   Google Scholar
• Leppert W. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Headache Rep 2011;15(4):271-9
   PubMed Web of Science ®Google Scholar
• Glare P, Aggarwal G, Clark K. Ongoing controversies in the pharmacological management of cancer pain. Intern Med J 2004;34(1-2):45-9
   Google Scholar
• Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014;123:25-33
   PubMed Web of Science ®Google Scholar
• Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 2008;108(3):495-505
   PubMed Web of Science ®Google Scholar
• Burness CB, Keating GM. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 2014;74(3):353-75
   PubMed Web of Science ®Google Scholar
• Cuomo A, Russo G, Esposito G, et al. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study. Am J Hosp Palliat Care 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011;25(5):471-7
   Google Scholar
• Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs 2010;70(1):57-72
   PubMed Web of Science ®Google Scholar
• Cachia E, Ahmedzai SH. Transdermal opioids for cancer pain. Curr Opin Support Palliat Care 2011;5(1):15-19
   PubMedGoogle Scholar
• Melilli G, Samolsky Dekel BG, Frenquelli C, et al. Transdermal opioids for cancer pain control in patients with renal impairment. J Opioid Manag 2014;10(2):85-93
   PubMedGoogle Scholar
• Paech MJ, Bloor M, Schug SA. New formulations of fentanyl for acute pain management. Drugs Today (Barc) 2012;48(2):119-32
   Google Scholar
• Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9(2):73-83
   PubMed Web of Science ®Google Scholar
• Routhier DD, Katz KD, Brooks DE. QTc prolongation and torsades de pointes associated with methadone therapy. J Emerg Med 2007;32(3):275-8
   Google Scholar
• Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol 2013;53(3):305-13
   Google Scholar
• Perlman R, Giladi H, Brecht K, et al. Intradialytic clearance of opioids: methadone versus hydromorphone. Pain 2013;154(12):2794-800
   Google Scholar
• Lundorff L, Sjogren P, Hansen OB, et al. Switching from high doses of pure mu-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study. J Opioid Manag 2013;9(4):255-62
   PubMedGoogle Scholar
• Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012;10(6):209-19
   PubMedGoogle Scholar
• Naing C, Yeoh PN, Aung K. A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain. SpringerPlus 2014;3:87
   Google Scholar
• Mitra F, Chowdhury S, Shelley M, Williams G. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med 2013;14(1):75-83
   Google Scholar
• Riemsma R, Forbes C, Harker J, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27(10):1907-30
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014;17(4):329-43
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin 2013;29(6):661-6
   PubMed Web of Science ®Google Scholar
• Niesters M, Proto PL, Aarts L, et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth 2014;113(1):148-56
   PubMed Web of Science ®Google Scholar
• Samolsky Dekel BG, Tomasi M, Vasarri A, et al. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol. J Opioid Manag 2014;10(1):29-38
   Google Scholar
• Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol 2014;32(16):1662-70
   PubMed Web of Science ®Google Scholar
• Vadalouca A, Moka E, Argyra E, et al. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 2008;4(4):213-50
   PubMedGoogle Scholar
• Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol 2014;32(16):1655-61
   PubMed Web of Science ®Google Scholar
• Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10(2):85-93
   PubMed Web of Science ®Google Scholar
• Nalamachu SR. Opioid rotation in clinical practice. Adv Ther 2012;29(10):849-63
   Google Scholar
• Caraceni A, Davies A, Poulain P, et al. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw 2013.11(Suppl 1):S29-36
   Google Scholar
• Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage 2013;46(4):573-80
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013;10:CD004311
   Google Scholar
• Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care 2012;29(1):70-9
   Google Scholar
• Cegielska-Perun K, Bujalska-Zadrozny M, Gasinska E, Makulska-Nowak HE. Enhancement of antinociceptive effect of morphine by antidepressants in diabetic neuropathic pain model. Pharmacol Rep 2014;66(2):228-34
   PubMed Web of Science ®Google Scholar
• Leppert W, Buss T. The role of corticosteroids in the treatment of pain in cancer patients. Curr Pain Headache Rep 2012;16(4):307-13
   Google Scholar
• Tawfic QA. A review of the use of ketamine in pain management. J Opioid Manag 2013;9(5):379-88
   Google Scholar
• Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012;30(29):3611-17
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;5:CD003188
   PubMed Web of Science ®Google Scholar
• Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012;2:CD003474
   Google Scholar
• Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006(4):CD006250
   PubMed Web of Science ®Google Scholar
• Wang X, Yang KH, Wanyan P, Tian JH. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials. Oncol Lett 2014;7(6):1997-2002
   Google Scholar
• Fallon MT, Laird BJ. A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliat Med 2011;25(5):597-603
   PubMed Web of Science ®Google Scholar
• Davis MP, Walsh D, Lagman R, LeGrand SB. Controversies in pharmacotherapy of pain management. Lancet Oncol 2005;6(9):696-704
   PubMed Web of Science ®Google Scholar
• Grond S, Meuser T. Weak opioids - an educational substitute for morphine? Curr Opin Anaesthesiol 1998;11(5):559-65
   Google Scholar